-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 22, Chinese State Drug Administration Bureau Center for Drug Evaluation (CDE) latest announcement, Cinda biological (HKSE stock code: 01801) PI3Kδ inhibitor parsaclisib oral breakthrough therapy has been incorporated into the proposed varieties, developing adaptation Symptoms are relapsed or refractory follicular lymphoma .
Managing lymphoma
Follicular lymphoma is a malignant tumor formed in the blood system, accounting for 22% of non-Hodgkin lymphoma (NHL) worldwide and 8.
In December 2018, Innovent and Incyte reached a strategic cooperation on three drug candidates in clinical trials, including parsaclisib.
In December 2020, in the Phase II clinical study of Innovent, eligible patients received 20 mg of Parsaclisib once a day for eight weeks, and then received 20 mg twice a week (Weekly Dosage Group [WG]) or daily A treatment plan of 2.
Data source is believed to be the official website of Biology
The data source is believed to be the official website of BiologyIt is reported that the world's first once-daily oral PI3K/CK1 inhibitor is TG's umbralisib (trade name UKONIQ), and it was approved by the U.
FDA leaves a message here